Top advances of the year: Precision oncology
Cancer · 2023
DOI: 10.1002/cncr.34743 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer, 2023. Verfasst von Aakash Desai und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, MayoClinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Precision Medicine, Lung Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 70 Literaturangaben.
Abstract (Originalsprache)
The advent of precision medicine has changed the landscape of oncologic biomarkers, drug discovery, drug development, and, more importantly, outcomes for patients with cancer. Precision oncology entails the genomic profiling of tumors to detect actionable aberrations. The advances in clinical next‐generation sequencing from both tumor tissue and liquid biopsy and availability of targeted therapies has rapidly entered mainstream clinical practice. In this review, recent major developments in precision oncology that have affected outcomes for patients with cancer are discussed. Rapid clinical development was seen of targeted agents across various mutational profiles such as KRASG12C (which was considered “undruggable” for almost 4 decades), Exon 20 insertions, and RET mutations. Approaches to precision chemotherapy delivery by the introduction of antibody drug conjugates in the armamentarium against lung cancer has been appreciated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, MayoClinic, Rochester, Minnesota, USA.
- Department of Internal Medicine, The University of Texas at Austin Dell Medical School, Austin, Texas, USA.
- Division of Cancer Medicine, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- MD Anderson Cancer Network, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Neha K Reddy, Vivek Subbiah
Zitieren
APA
Desai, A., Reddy, N. K., & Subbiah, V. (2023). Top advances of the year: Precision oncology. Cancer. https://doi.org/10.1002/cncr.34743
Vancouver
Desai A, Reddy NK, Subbiah V. Top advances of the year: Precision oncology. Cancer. 2023. doi:10.1002/cncr.34743
BibTeX
@article{Desai2023,
author = {Desai, Aakash and Reddy, Neha K and Subbiah, Vivek},
title = {Top advances of the year: Precision oncology},
journal = {Cancer},
year = {2023},
doi = {10.1002/cncr.34743}
}
EUVIMED